Grace Therapeutics (GRCE)
NASDAQ:GRCE
Top Page
Grace Therapeutics
(NASDAQ:GRCE)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.50
▼(-1.96% Downside)
Action:ReiteratedDate:04/09/26
The score is primarily held down by weak financial performance driven by pre-revenue status, ongoing losses, and persistent cash burn, despite a low-debt balance sheet. Technicals are also soft with the price below key moving averages and weak momentum. Valuation contributes little support because earnings are negative and no dividend yield is provided.
Positive Factors
Zero debt and sizable equity cushion
Zero reported debt and roughly $64.9M of equity give Grace financial flexibility to fund clinical programs without immediate refinancing. This durable capital cushion lowers near-term solvency risk and supports R&D runway, although additional financing may still be required as programs advance.
Negative Factors
Pre-revenue business model
Grace remains pre-revenue with no commercial sales, meaning its long-term viability depends on successful clinical outcomes or licensing. This structural lack of operating revenue forces reliance on capital markets and increases execution risk until a sustainable revenue stream is established.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero debt and sizable equity cushion
Zero reported debt and roughly $64.9M of equity give Grace financial flexibility to fund clinical programs without immediate refinancing. This durable capital cushion lowers near-term solvency risk and supports R&D runway, although additional financing may still be required as programs advance.
Read all positive factors
Grace Therapeutics (GRCE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$55.24M
Dividend YieldN/A
Average Volume (3M)58.56K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue GrowthN/A
EPS Growth45.97%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding15,474,026
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.72K
Enterprise Value/Ebitda-4.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$9.19M
Grace Therapeutics Business Overview & Revenue Model
Company Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrh...
How the Company Makes Money
null...
Grace Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 196.00K |
| Gross Profit | -4.12K | 0.00 | -11.00K | 0.00 | 0.00 | 120.00K |
| EBITDA | -7.76M | -16.67M | -14.62M | -18.12M | -15.34M | -9.79M |
| Net Income | -6.84M | -9.57M | -12.85M | -42.43M | -9.82M | -19.68M |
Balance Sheet | ||||||
| Total Assets | 68.49M | 71.99M | 73.30M | 79.12M | 128.62M | 62.46M |
| Cash, Cash Equivalents and Short-Term Investments | 18.67M | 22.13M | 23.00M | 27.89M | 43.66M | 60.73M |
| Total Debt | 0.00 | 0.00 | 0.00 | 485.00K | 295.00K | 86.00K |
| Total Liabilities | 3.60M | 5.38M | 11.56M | 11.17M | 20.35M | 6.80M |
| Stockholders Equity | 64.89M | 66.61M | 61.74M | 67.95M | 108.27M | 55.66M |
Cash Flow | ||||||
| Free Cash Flow | -10.13M | -14.90M | -12.36M | -15.93M | -17.23M | -14.39M |
| Operating Cash Flow | -10.13M | -14.90M | -12.33M | -15.91M | -17.23M | -14.32M |
| Investing Cash Flow | 0.00 | 0.00 | 104.00K | 13.15M | -3.52M | -9.86M |
| Financing Cash Flow | 17.75M | 14.03M | 7.36M | 304.00K | 0.00 | 59.49M |
Grace Therapeutics Technical Analysis
Negative
3.57
Price Trends
4.03
Negative
3.71
Negative
3.41
Positive
Market Momentum
<0.01
Positive
39.39
Neutral
24.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRCE, the sentiment is Negative. The current price of 3.57 is below the 20-day moving average (MA) of 4.36, below the 50-day MA of 4.03, and above the 200-day MA of 3.41, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 39.39 is Neutral, neither overbought nor oversold. The STOCH value of 24.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRCE.
Grace Therapeutics Risk Analysis
Grace Therapeutics disclosed 51 risk factors in its most recent earnings report. Grace Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Grace Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $80.72M | -2.08 | -291.42% | ― | ― | 61.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $55.37M | >-0.01 | ― | ― | ― | 21.48% | |
46 Neutral | $55.24M | -4.61 | -10.61% | ― | ― | 45.97% | |
42 Neutral | $49.44M | -1.22 | -28.16% | ― | -55.88% | 6.14% | |
42 Neutral | $12.16M | -1.02 | -333.32% | ― | ― | -9.80% |
* Healthcare Sector Average
GRCE
Grace Therapeutics
3.57
1.63
84.02%
PYPD
PolyPid
4.23
1.78
72.65%
ALGS
Aligos Therapeutics
7.99
4.00
100.25%
INKT
MiNK Therapeutics
11.15
3.57
47.10%
CVKD
Cadrenal Therapeutics, Inc.
4.85
-9.42
-66.01%
Grace Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Grace Therapeutics Enhances Executive Severance and Change‑in‑Control Terms
Neutral
Jan 12, 2026
On January 10, 2026, Grace Therapeutics amended its employment letter agreements with its CEO and four senior executives, revising severance protections and change-in-control terms for these key officers. Under the new terms, executives terminated...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.